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Impact of pulmonary hypertension on
transplant outcomes in pediatric
cardiomyopathy patients
PHTN has historically been shown to be a
signiﬁcant risk factor for morbidity and mortal-
ity in patients awaiting heart transplantation. In
this setting, acute donor right heart failure may
develop requiring inotropic support, ECMO,
prolonged ventilation, and this may even cause
mortality. Elevation of both trans-pulmonary
pressure gradient and PVR has been identiﬁed as
risk factors for early morbidity and mortality
after heart transplantation (1–3). Even modest
degrees of PHTN can complicate post-transplant
management (4) and severe PHTN is thus
considered a contraindication to heart transplan-
tation.
Recent studies have suggested that PHTN may
not continue to be a signiﬁcant risk factor (5) for
transplant outcome, reﬂecting availability of new
agents useful in management. These studies have
been limited by small patient numbers (6), and
data are scarce in children (7).
Most studies describing eﬀects of PHTN on
transplant outcomes have combined multiple
diagnoses (8). In this study, we sought to
evaluate pediatric heart transplant outcomes of
patients with cardiomyopathies alone. We have
restricted focus to patients with cardiomyopa-
thies as in this disease PHTN is thought to be
secondary to elevated left ventricular end-dia-
stolic pressure, so it is expected to be reversible
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Abstract: Controversy exists over whether PHTN in heart transplant
candidates increases post-transplant mortality. We performed analysis
of data reported to UNOS for children who underwent primary heart
transplantation for cardiomyopathy from January 1994 to June 2010.
Patients were divided into two groups depending on their pre-transplant
TPG: no-PHTN (TPG £ 12 mmHg) and PHTN (TPG >12 mm Hg).
A total of 6139 children underwent transplantation of whom 2456
(40%) were for cardiomyopathies; 1322 (54%) of these had catheteri-
zation data available. The PHTN group (mean TPG 19.5 ± 8.6) had
312 patients and no-PHTN (TPG 6.7 ± 4.0) had 1010. Mortality at
one month (4.5% vs. 2.3%) and three months (6.1% vs. 3.1%) post-
transplant was signiﬁcantly higher in the PHTN than the no-PHTN
group with an odds ratio of 2 (p < 0.05). There was no signiﬁcant eﬀect
of PHTN on early mortality in children <1 yr age. There was no sig-
niﬁcant improvement in early survival for transplants performed after
compared to before 2003 in patients with PHTN despite availability of
pulmonary dilators. Pre-transplant PHTN increases early post-trans-
plant mortality in pediatric cardiomyopathy patients above one yr of
age. There has been no signiﬁcant improvement in the outcome of this
group over the last seven yr.
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with placement of a normal heart. Our aim is to
compare the post heart transplant mortality and
morbidity of children with cardiomyopathies and
PHTN to children with normal pulmonary pres-
sures, examining eﬀects of patient age and era.
Methodology
We performed a retrospective analysis of all data
reported to the UNOS database for pediatric
patients (ages from 0 to 18 yr) who underwent
primary heart transplantation from January 1994
to June 2010 for a diagnosis of cardiomyopathy.
Children with congenital heart disease requiring
heart transplant were excluded because they can
have PHTN from multiple mechanisms. Cathe-
terization data were not available on all patients
in the database, so we included only patients with
pre-transplant pulmonary pressure data avail-
able. We used the TPG as a measure of PHTN
rather than PVR as PVR is cardiac output
dependant and these patients generally have
low cardiac output, making small variations in
cardiac output have a large impact on calculated
PVR. TPG was calculated by the diﬀerence
between the mean pulmonary artery pressure
and mean pulmonary capillary wedge pressure.
Patients with cardiomyopathy were divided
into two groups based on their pre-transplant
TPG: no-PHTN (TPG £ 12 mmHg) and PHTN
(TPG >12 mmHg). Demographic data gathered
included gender, race, and age at transplantation.
Clinical characteristics gathered included medical
urgency status at transplantation, transplant wait
time, need for ventilation, inotropic support,
ECMO, need for pre-transplant dialysis, rate of
infections requiring antibiotics, and DRWR.
Demographic and clinical characteristics were
compared between groups. Measures of early
post-transplant morbidity were gathered includ-
ing length of hospital stay after transplantation,
need for post-transplant dialysis, rate of post-
transplant infection, and incidence of acute
rejection. Mortality was compared between
groups at one month, three months, one yr,
and for the entire post-transplant period sepa-
rately.
Statistical analysis was performed using SAS
version 9.2 (Cary, NC, USA). Demographics
pre- and post-transplant characteristics were
compared between groups using Fishers exact
and chi-square tests. T-test and Mann–Whitney
U-test were used to compare continuous vari-
ables such as age, transplant wait time, ischemic
time and length of hospital stay between patient
subgroups. Mean and standard deviation were
calculated for all continuous variables. Actuarial
survival curves were derived using Kaplan–
Meiers product-limit method, and log-rank tests
were performed to compare survival between
patient subgroups univariately. Cox proportional
hazard regression was used to correlate patients
pre-transplant characteristics with duration of
survival.
As the UNOS Standard Analysis and Research
ﬁles provide de-identiﬁed data, consent exemp-
tion status was granted by the Wayne State
University Institutional Review Board.
Results
A total of 6139 children underwent heart trans-
plantation from January 1994 to June 2010, of
which 2456 (40%) had a listing diagnosis of
cardiomyopathy. One thousand three hundred
and twenty-two (54%) of cardiomyopathy pa-
tients had catheterization data available and thus
qualiﬁed for the study. Among them, only 52
(3.9%) were lost to follow-up. Cardiomyopathy
patients without catheterization data available
had a signiﬁcantly lower overall mortality than
those with catheterization data (22% vs. 27%;
p < 0.01). On a covariate adjusted basis, the
mortality between catheter and non-catheter
patients was not signiﬁcantly diﬀerent.
The study group comprised 312 patients in the
PHTN group and 1010 in the no-PHTN group.
Patient demographics are presented in Table 1.
Age, gender, and racial distribution did not diﬀer
between groups.
Clinical characteristics are shown in Table 2.
Transplant wait time was signiﬁcantly longer in
the PHTN group (p = 0.01). Indicators of pre-
transplant severity such as medical urgency status
need for mechanical ventilation, inotropic sup-
port, ECMO support, dialysis, and infections
requiring antibiotic use were not diﬀerent between
Table 1. Demographics
PHTN group
(N = 312)
No-PHTN group
(N = 1010) p-Value
Age, mean € s.d. 9.3 € 6.0 9.6 € 6.3 0.3
<1 yr (N = 130), n (%) 26 (8) 104 (10)
1–10 yr (N = 502), n (%) 128 (41) 374 (37)
>10 yr (N = 690), n (%) 158 (51) 532 (53)
Gender, n (%)
Male 176 (56) 535 (53) 0.3
Female 136 (44) 475 (47)
Race, n (%)
Caucasian 153 (49) 545 (54) 0.2
African American 81 (26) 270 (27)
Hispanic 48 (15) 121 (12)
Other 30 (10) 74 (7)
Buddhe et al.
368
groups. A similar percentage of patients were on
inotropes/vasodilators at the time of obtaining
hemodynamics in both groups. The DRWR dis-
tribution, ischemic time, and number of patients
receiving hearts with ‡4 h ischemic time were not
signiﬁcantly diﬀerent between groups.
Post-transplant morbidity was compared be-
tween the groups as shown in Table 3. Duration
of hospital stay prior to discharge, need for re-
operation, post-transplant dialysis, and incidence
of post-transplant infections were similar be-
tween groups. The number of acute rejection
episodes before discharge and within one yr post-
transplant was not signiﬁcantly diﬀerent between
groups.
Post-transplant mortality is compared between
groups in Table 4. In the entire group, mortality
at one month (4.5% vs. 2.3%) and three months
(6.1% vs. 3.1%) post-transplant was signiﬁcantly
higher in the PHTN than the no-PHTN group.
The odds ratio at one and three months for
mortality with PHTN is 2.0 and at one yr it is 1.6
(p < 0.05). One yr and overall mortality was
higher in the PHTN group but overall mortality
Table 2. Clinical characteristics
PHTN group
(N = 312)
No-PHTN group
(N = 1010) p-Value
Urgency status, n (%)
1A 143 (46) 541 (54) 0.09
1B 40 (13) 103 (10)
2 59 (19) 179 (18)
Other 70 (22) 187 (18)
TPG, mean € s.d. 19.5 € 8.6 6.7 € 4.0 <0.01
Diagnosis, n (%)
Dilated CMP 238 (76) 873 (86) <0.01
Restrictive CMP 58 (19) 93 (9)
Hypertrophic CMP 16 (5) 44 (4)
Use of inotropes/vasodilators,
n (%)
117 (37.5) 325 (32) 0.08
Transplant wait time (days),
mean € s.d.
112 € 14 86 € 5 0.01
Inotropic support Y, n (%) 179 (57) 547 (54) 0.3
Ventilation support Y, n (%) 42 (13) 113 (11) 0.3
ECMO support Y, n (%) 14 (4) 24 (2) 0.07
DRWR, n (%)
Low (<0.8) 29 (9) 79 (8) 0.4
Ideal (0.8–2.0) 254 (83) 860 (85)
Oversized (>2.0) 25 (8) 66 (7)
Dialysis support Y, n (%) 5 (2) 21 (2) 0.8
IV antibiotic support Y, n (%) 54 (17) 145 (14) 0.4
Ischemic time (h), mean € s.d. 3.2 € 1.3 3.1 € 1.0 0.4
Ischemic time >4 h Y, n (%) 55 (18) 182 (18) 1.0
Table 3. Post-transplant morbidity
PHTN
group
(N = 312)
No-PHTN
group
(N = 1010) p-Value
Cardiac re-operation Y, n (%) 17 (5) 47 (5) 0.5
Dialysis support Y, n (%) 10 (3) 29 (3) 0.7
Acute rejection before
discharge Y, n (%)
16 (5) 69 (7) 0.8
Rejection within 1 yr Y, n (%) 81 (26) 253 (25) 0.1
Drug treated infection Y, n (%) 49 (16) 133 (13) 0.3
Hospital stay (days), mean € s.d. 20.5 € 1.7 19.6 € 0.9 0.6
Table 4. Post-transplant mortality
PHTN
group
(N = 312)
No-PHTN
group
(N = 1010) p-Value
1-month mortality, n (%)
Infant 0/26 (0) 6/104 (6) 0.6
Children 14/286 (5) 17/906 (2) <0.01
All 14 (4.5) 23 (2.3) 0.04
All pre-2003 9/179 (5) 19/499 (4) 0.5
All post-2003 5/133 (4) 4/511 (1) 0.02
3-month mortality, n (%)
Infant 1 (4) 6 (6) 1.0
Children 18 (6) 25 (3) 0.01
All 19 (6) 31 (3) 0.03
All pre-2003 13 (7) 25 (5) 0.2
All post-2003 6 (5) 6 (1) 0.02
1-yr mortality, n (%)
Infant 4 (15) 8 (8) 0.2
Children 29 (10) 63 (7) 0.09
All 33 (11) 71 (7) 0.05
All pre-2003 20 (11) 50 (10) 0.6
All post-2003 13 (10) 21 (4) 0.01
Overall mortality, n (%)
Infant 5 (19) 22 (21) 1.0
Children 92 (32) 241 (27) 0.07
All 97 (31) 263 (26) 0.08
All pre-2003 72 (40) 199 (40) 1.0
All post-2003 25 (19) 64 (12.5) 0.06
Fig. 1. Kaplan–Meier survival curve. Odds ratio for mor-
tality at one month: 2.0. Odds ratio for mortality at
three months: 2.0. Odds ratio for mortality at one yr: 1.6.
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did not reach statistical signiﬁcance (Fig. 1). The
hazard ratio for overall mortality for the PHTN
group on multivariate analysis was not signiﬁ-
cant at 0.97 (p = 0.97). When used as continu-
ous variable, TPG had no signiﬁcant eﬀect on
mortality. Using a TPG of 15 in the analysis
rather than 12 produced similar results (not
shown). On multivariate analysis, age more than
one yr, transplant after 2003 and pre-transplant
hospitalization status were signiﬁcant predictors
of overall mortality.
Among the 1322 patients with CMP, 1111
(84%) had dilated CMP, 151 (11.4%) had
restrictive CMP, and 60 (4.5%) had hypertrophic
CMP. The 1135 patients without catheterization
data had a similar distribution of CMP subtypes.
Among patients with catheterization data avail-
able, there were more patients with RCM in the
PHTN group (Table 2), but the overall mortality
was not signiﬁcantly diﬀerent between diagnoses:
DCM: 312 (28%), RCM: 32 (21%), and HCM:
16 (27%) (p = 0.2).
When patients were stratiﬁed by age, PHTN
had no eﬀect on early mortality in children
transplanted <1 yr age, but it was associated
with increased mortality in children >1 yr age.
There was no era eﬀect apparent in early survival
in PHTN group before vs. after 2003 when
pulmonary vasodilator therapy became widely
available.
Discussion
In our analysis of the UNOS database, we have
found short-term mortality at one and three -
months post-transplant to be signiﬁcantly higher
in pediatric cardiomyopathy patients with PHTN
than if the TPG is normal. There was no eﬀect of
era on mortality before and after 2003 when
pulmonary vasodilator therapy became widely
available. The mortality inﬂuence of PHTN was
not seen in infants. In patients with PHTN,
ischemic time of the transplanted heart or use of
oversized donors did not have a signiﬁcant eﬀect
on mortality.
Heart transplantation is an excellent option for
children with end-stage cardiomyopathy, some
forms of complex congenital heart disease and
some infants and children with failed surgical
interventions. Without transplant children with
end-stage cardiomyopathy have a poor prognosis
(9). PHTN in patients awaiting transplant can
complicate postoperative care. Several studies
have shown that elevated TPG or PVR is
associated with high post-transplant mortality
(1–3, 10–15). Historically mortality was found to
be higher in children with PHTN, particularly in
those who were over one yr of age (3). PHTN
can preclude oﬀering transplant to children with
end-stage heart disease. We have found that
overall mortality post-transplant is signiﬁcantly
higher in pediatric patients with PHTN but not
in infants. Infants seem protected from mortality
from PHTN as the PVR is rarely ﬁxed and it
seems to decrease more rapidly after heart
transplantation than in children or adults (3).
The long-term mortality in the PHTN group is
not signiﬁcantly greater than with normal pul-
monary pressures. This could be because the
long-term mortality more often is caused by
factors other than PHTN that may be similar in
both groups. Although the initial small diﬀerence
in early mortality persists long term, the mortal-
ity from other causes is signiﬁcantly higher
making the diﬀerence not statistically signiﬁcant.
Recent studies in adults suggest that PHTN if
reversible is not associated with poor transplant
outcomes and that these patients can be trans-
planted safely (6, 16–20). In pediatric patients
with cardiomyopathy and PHTN, it was shown
that use of sildenﬁl, bosentan, nitric oxide (21),
prostacyclin (8), PGE1 (22), and ventricular
assist devices (23) may improve outcomes com-
parable to patients without PHTN and that
pulmonary resistance index normalized early
after transplantation (24). However, the impact
of the current practice of excluding patients with
signiﬁcantly elevated non-reactive PVR on out-
comes cannot be excluded (25). Contrary ﬁnd-
ings in other studies have shown that PHTN
even if reactive is associated with poor outcomes
(26) and increased mortality (27). To evaluate
the eﬀects of era on outcomes, we performed
subgroup analysis to compare mortality in
patients transplanted before and after 2003
when the use of selective pulmonary vasodila-
tors became common. The survival has signif-
icantly improved in both groups transplanted
after 2003 (Table 4), but mortality in the PHTN
group still remains signiﬁcantly higher than the
no-PHTN group.
Previous studies have shown that in patients
with PHTN, transplanting a heart with longer
ischemic time may increase mortality (28). How-
ever in our study, we did not notice any eﬀect of
ischemic time on mortality in PHTN patients. It
was also found in previous studies that use of an
oversized donor may be beneﬁcial in patients
with PHTN (29). When we compared outcomes
in the PHTN group, there was a trend toward
lower mortality with oversized DRWR (28%)
compared to ideal DRWR (30%) and low
DRWR (41%), but it did not reach statistical
signiﬁcance (p = 0.4).
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Despite advances in management strategies for
pediatric cardiomyopathy patients with PHTN,
early survival is inferior in these patients com-
pared to those without PHTN. Although PHTN
had no detrimental eﬀect on early post-trans-
plant morbidity such as length of post-transplant
hospital stay, need for reoperations or dialysis,
there were no data available in the UNOS
database about indicators of right heart failure
such as need for ECMO or assist device support
post-transplant and thus could not be analyzed.
Limitations
This study was performed using the UNOS
database. Limitations that are inherent to a
retrospective database study apply here. Only
54% of children with cardiomyopathies had
cardiac catheterization data available and if all
had data, our analysis may have produced
diﬀerent conclusions. A second limitation of the
study is that although we had data on the
number of patients who were on inotropes/
vasodilators at the time of cardiac catheteriza-
tion, the reversibility of PHTN was not docu-
mented and thus could not be analyzed.
Conclusions
PHTN continues to have a signiﬁcant impact on
early post-transplant mortality in pediatric pa-
tients with cardiomyopathies despite availability
of agents that lower PVR. The use of oversized
donors or grafts with shorter ischemic times does
not seem to aﬀect the outcomes. Infants seem to
be protected from the eﬀects of PHTN.
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